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Interferon-␥ (IFN-␥) is known primarily for its roles in
immunological responses but also has been shown to
affect fat metabolism and adipocyte gene expression. To
further investigate the effects of IFN-␥ on fat cells, we
examined the effects of this cytokine on the expression
of adipocyte transcription factors in 3T3-L1 adipocytes.
Although IFN-␥ regulated the expression of several adipocyte transcription factors, IFN-␥ treatment resulted
in a rapid reduction of both peroxisome proliferatoractivated receptor (PPAR) protein and mRNA. A 48-h
exposure to IFN-␥ also resulted in a decrease of both
CCAAT/enhancer-binding ␣ and sterol regulatory element binding protein (SREBP-1) expression. The short
half-life of both the PPAR␥ mRNA and protein likely
contributed to the rapid decline of both cytosolic and
nuclear PPAR␥ in the presence of IFN-␥. Our studies
clearly demonstrated that the IFN-␥-induced loss of
PPAR␥ protein is partially inhibited in the presence of
two distinct proteasome inhibitors. Moreover, IFN-␥
also inhibited the transcription of PPAR␥, which was
accompanied by a decrease in PPAR␥ mRNA accumulation. In addition, exposure to IFN-␥ resulted in a substantial increase in STAT 1 expression and a small increase in STAT 3 expression. IFN-␥ treatment of 3T3-L1
adipocytes (48 –96 h) resulted in a substantial inhibition
of insulin-sensitive glucose uptake. These data clearly
demonstrate that IFN-␥ treatment results in the development of insulin resistance, which is accompanied by
the regulation of various adipocyte transcription factors, in particular the synthesis and degradation of
PPAR␥.

The adipocyte plays an active role in a variety of physiological and pathological processes regulating energy metabolism.
The recent consideration of adipose tissue as an endocrine
organ that secretes a variety of unrelated bioactive molecules
has broadened our understanding of adipocyte function to exceed its previously considered passive role in lipid metabolism.
A number of cell lines are available for studying adipocytes.
The 3T3-L1 cell line differentiates under the controlled conditions of cell culture from fibroblasts, or preadipocytes, to cells
with the morphological and biochemical properties of adipocytes (1, 2). The 3T3-L1 adipocytes are comparable with native
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adipocytes as they have the ability to accumulate lipid, respond
to insulin, and secrete leptin. The major transcription factors
involved in adipocyte gene regulation include peroxisome proliferator-activated receptor ␥, proteins belonging to the
CCAAT/enhancer-binding protein family, and adipocyte determination and differentiation-dependent factor 1, also known as
sterol regulatory element-binding protein (reviewed in Refs. 3
and 4).
Recent studies have also suggested that the signal transducer and activator of transcription (STAT)1 family of transcription factors may also be important in fat cells. The STAT
family of transcription factors is comprised of seven family
members (STATs 1, 2, 3, 4, 5A, 5B, and 6) that, in response to
the stimulation of various receptors, mainly those for cytokines, are phosphorylated on tyrosine residues, which causes
their translocation to the nucleus. Each STAT family member
shows a distinct pattern of activation by cytokines and upon
nuclear translocation can regulate the transcription of particular genes in a cell- or tissue-specific manner (5). In fat cells,
the expression of STATs 1, 5A, and 5B is highly induced during
differentiation and correlates with lipid accumulation (6, 7).
The regulation of STAT expression has also been investigated
in NIH 3T3 cells ectopically overexpressing C/EBPs ␤ and ␦, a
condition that results in adipogenesis (8). In these studies, the
expression of STATs 1, 5A, and 5B was induced in a PPAR␥
ligand-dependent fashion during adipogenesis (9). STATs 3 and
6 are also expressed in adipocytes, but the expression of these
proteins does not change during differentiation. However, the
tyrosine phosphorylation of STAT 3 occurs following the induction of differentiation, and studies with antisense STAT 3 suggest that this protein may be important in adipogenesis (10).
Although the functions of STATs in fat cells have not been
identified, numerous studies suggest that these transcription
factors may be important regulators of adipocyte gene
expression.
Interferon-␥ (IFN-␥) is primarily known for its roles in immunological responses but also has been shown to affect fat
metabolism and adipocyte gene expression. In adipocytes,
IFN-␥ treatment results in a decrease of lipoprotein lipase
activity and increased lipolysis (11). In 3T3-F442 adipocytes,
exposure to IFN-␥ results in a decreased expression of lipoprotein lipase and fatty acid synthase. Also in various rodent
preadipocyte cell lines, IFN-␥ inhibits the differentiation of
preadipocytes (12–14). We have recently shown that acute
IFN-␥ treatment of cultured and native adipocytes results in a

1
The abbreviations used are: STAT, signal transducer and activator
of transcription; C/EBP, CCAAT/enhancer-binding protein; ERK, extracellular signal-regulated kinase; TZD, thiazolidinedione; DMEM, Dulbecco’s modified Eagle’s medium; ENG, englitazone; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PPAR,
peroxisome proliferator-activated receptor; SREBP-1, sterol regulatory
element-binding protein.
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IFN-␥ Effects on PPAR␥
dose- and time-dependent activation of STATs 1 and 3 (15).
Exposure of adipocytes to IFN-␥ results in the tyrosine phosphorylation and nuclear translocation of STATs 1 and 3 in fat
cells. Because IFN-␥ has effects on adipocyte gene expression,
we examined the effects of this cytokine on the expression of a
variety of adipocyte transcription factors.
Although we observed that IFN-␥ affected the expression of
a number of adipocyte transcription factors, the most profound
effect of IFN-␥ was on the expression of PPAR␥. PPAR␥ is a
member of the nuclear hormone superfamily and exists as two
isoforms, PPAR␥1 and PPAR␥2, which are transcribed from
the same gene by the use of alternative promoters (16).
PPAR␥2 is 30 amino acids longer than PPAR␥1 and is largely
adipocyte-specific. Although expressed in a variety of other
tissues, PPAR␥1 is also predominately expressed in fat (17).
Thiazolidinediones (TZDs) are high affinity synthetic ligands of
PPAR␥ and have recently been shown to affect the degradation
of this transcription factor (18). Our studies with IFN-␥ also
indicate that PPAR␥ is targeted to the proteasome for degradation, but this is not the only mechanism for the substantial
effect that IFN-␥ has on PPAR␥ expression. Our findings indicate that a newly identified inhibitor of PPAR␥ expression,
IFN-␥, results in a substantial loss of PPAR␥ expression by
regulating two cellular events as follows: 1) targeting PPAR␥ to
the proteasome for degradation and 2) inhibiting the synthesis
of PPAR␥. Prolonged IFN-␥ treatment of 3T3-L1 adipocytes
also results in the development of insulin resistance and regulation of other adipocyte transcription factors and supports
the hypothesis that PPAR␥ is involved in conferring insulin
sensitivity.
EXPERIMENTAL PROCEDURES

Materials—Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Life Technologies, Inc. Bovine and fetal bovine serum was
obtained from Sigma and Life Technologies, Inc., respectively. Murine
interferon-␥ (IFN-␥) was purchased from Roche Molecular Biochemicals. Actinomycin D was purchased from Calbiochem. Cycloheximide
was purchased from Sigma. The nonphospho STAT antibodies were
either monoclonal IgGs purchased from Transduction Laboratories or
polyclonal IgGs from Santa Cruz Biotechnology Inc. A highly phosphospecific polyclonal antibody for STAT 1 (Y701) was provided by Quality
Controlled Biochemicals. PPAR␥ was a mouse monoclonal antibody
from Santa Cruz Biotechnology Inc. SREBP-1, C/EBP␣, and ERK1/
ERK2 were rabbit polyclonal antibodies from Santa Cruz Biotechnology
Inc.
Cell Culture—Murine 3T3-L1 preadipocytes were plated and grown
to 2 days postconfluence in DMEM with 10% bovine serum. Medium
was changed every 48 h. Cells were induced to differentiate by changing
the medium to DMEM containing 10% fetal bovine serum, 0.5 mM
3-isobutyl-1-methylxanthine, 1 M dexamethasone, and 1.7 M insulin.
After 48 h this medium was replaced with DMEM supplemented with
10% fetal bovine serum, and cells were maintained in this medium until
utilized for experimentation.
Preparation of Whole Cell Extracts—Monolayers of 3T3-L1 adipocytes were rinsed with phosphate-buffered saline and then harvested in
a nondenaturing buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1
mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 M
phenylmethylsulfonyl fluoride, 1 M pepstatin, 50 trypsin inhibitory
milliunits of aprotinin, 10 M leupeptin, and 2 mM sodium vanadate.
Samples were extracted for 30 min on ice and centrifuged at 15,000 rpm
at 4 °C for 15 min. Supernatants containing whole cell extracts were
analyzed for protein content using a BCA kit (Pierce) according to the
manufacturer’s instructions.
Preparation of Nuclear/Cytosolic Extracts—Cell monolayers were
rinsed with phosphate-buffered saline and then harvested in a nuclear
homogenization buffer (NHB) containing 20 mM Tris (pH 7.4), 10 mM
NaCl, and 3 mM MgCl2. Nonidet P-40 was added to a final concentration
of 0.15%, and cells were homogenized with 16 strokes in a Dounce
homogenizer. The homogenates were centrifuged at 1500 rpm for 5 min.
Supernatants were saved as cytosolic extract, and the nuclear pellets
were resuspended in 0.5 volume of NHB and centrifuged as before. The
pellet of intact nuclei was resuspended again in 0.5 of the original
volume of NHB and centrifuged again. A small portion of the nuclei was
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used for trypan blue staining to examine the integrity of the nuclei. The
majority of the pellet (intact nuclei) was resuspended in an extraction
buffer containing 20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, and 25% glycerol. Nuclei were extracted for 30 min on ice
and then placed at room temperature for 10 min. Two hundred units of
DNase I were added to each sample, and tubes were inverted and
incubated an additional 10 min at room temperature. Finally, the
sample was subjected to centrifugation at 15,000 rpm at 4 °C for 30 min.
Supernatants containing nuclear extracts were analyzed for protein
content.
Gel Electrophoresis and Immunoblotting—Proteins were separated
in 5, 7.5, or 12% polyacrylamide (acrylamide from National Diagnostics)
gels containing sodium dodecyl sulfate (SDS) according to Laemmli (19)
and transferred to nitrocellulose (Bio-Rad) in 25 mM Tris, 192 mM
glycine, and 20% methanol. Following the transfer, the membrane was
blocked in 4% milk for 1 h at room temperature. Results were visualized
with horseradish peroxidase-conjugated secondary antibodies (Sigma)
and enhanced chemiluminescence (Pierce).
RNA Analysis—Total RNA was isolated from cell monolayers with
TriZOL (Life Technologies, Inc.) according to the manufacturer’s instruction with minor modifications. For Northern blot analysis, 20 g of
total RNA was denatured in formamide and electrophoresed through a
formaldehyde-agarose gel. The RNA was transferred to Zeta Probe-GT
(Bio-Rad), cross-linked, hybridized, and washed as previously described
(20). Probes were labeled by random priming using the Klenow fragment (Promega) and [␣-32P]dATP (PerkinElmer Life Sciences).
Determination of 2-Deoxyglucose—The assay of 2-[3H]deoxyglucose
was performed as previously described (21). Prior to the assay, fully
differentiated 3T3-L1 adipocytes were serum-deprived for 2– 4 h. Uptake measurements were performed in triplicate under conditions
where hexose uptake was linear, and the results were corrected for
nonspecific uptake and absorption determined by 2-[3H]deoxyglucose
uptake in the presence of 5 M cytochalasin B (Sigma). Nonspecific
uptake and absorption were always less than 10% of the total uptake.
Nuclei Isolation and Run-on Transcription Assays—Following exposure of fully differentiated adipocytes to IFN-␥ for 1 h, the cell monolayers (six 10-cm plates per time point) were washed once with ice-cold
phosphate-buffered saline and nuclei were isolated, and run-on transcription assays were performed as we have previously described (20).
RESULTS

The expression of adipocyte transcription factors was examined following a time course of IFN-␥ treatment on fully differentiated 3T3-L1 adipocytes. As shown in Fig. 1, immunoblotting of whole cell extracts demonstrated that IFN-␥ treatment
resulted in a significant decrease in PPAR␥2 (upper band) and
-␥1(lower band) within 24 h and resulted in a notable decline in
C/EBP␣. The expression of STATs 1 and 3 increased following
a 24-h IFN-␥ treatment. The expression of STATs 5A, 5B, and
6 was not regulated by exposure to IFN-␥ treatment. Also, the
expression of SREBP-1 decreased after a 48-h treatment. The
spliced 67-kDa form of SREBP-1 was similarly decreased with
IFN-␥ treatment (data not shown).
As shown in Fig. 1, a 24-h treatment of IFN-␥ resulted in a
substantial loss of PPAR␥2 and -␥1 protein expression. Therefore, we examined the effects of IFN-␥ over a 24-h time course.
Whole cell extracts were isolated from fully differentiated
3T3-L1 adipocytes that were treated with IFN-␥ for the various
times indicated in Fig. 2. Interestingly, IFN-␥ resulted in a
substantial loss of PPAR␥2 and -␥1 expression within 6 h. In
addition, we observed a striking increase in STAT 1 expression
between 8 and 12 h and a small increase in STAT 3 during this
time period. There was no change in STAT 5A during this time
course. JAK 1, the kinase that activates STAT 1 in adipocytes,
increases slightly with IFN-␥ treatment. In addition, fatty acid
synthase expression decreased with IFN-␥ treatment.
Clearly, an analysis of whole cell extracts reveals a substantial loss of PPAR␥2 and -␥1 expression in adipocytes following
IFN-␥ treatment. However, it was unclear whether IFN-␥ had
any effect on the amount of PPAR␥ proteins present in the
adipocyte nucleus. To further examine the inhibition of PPAR␥
by IFN-␥, we performed another time course in which adipo-
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FIG. 1. The effects of IFN-␥ on the expression of adipocyte
transcription factors. Whole cell extracts were prepared from fully
differentiated 3T3-L1 adipocytes following a treatment with 100
units/ml IFN-␥ for 0, 24, 48, 72, or 96 h. Cells were treated every 24 h
with a fresh bolus of IFN-␥. Extracts were prepared as described under
“Experimental Procedures.” One hundred g of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. The molecular mass of each protein is indicated
to the left of the blot in kilodaltons. The detection system was horseradish peroxidase-conjugated secondary antibodies (Sigma) and enhanced chemiluminescence (Pierce). This is a representative experiment independently performed three times.

cytes were fractionated to isolate cytosolic and nuclear extracts. As shown in the top panel of Fig. 3, the majority of
PPAR␥2 and -␥1 protein was present in the nucleus, and the
amount of nuclear PPAR␥ protein was substantially reduced
after 6 h. A darker exposure of this blot indicates the presence
of PPAR␥ proteins in the cytosol in untreated adipocytes and
cells that were exposed to IFN-␥ for 30 min. However, following
a 6-h or greater IFN-␥ treatment, there was no detectable
PPAR␥2 or -␥1 in the cytosol and a significant loss of both
PPAR␥ isoforms in the nucleus. We also observed an increase
in STAT 1 in the cytosol between 6 and 12 h and the presence
of activated STAT 1 in the nucleus following a 30-min treatment with IFN-␥. Detection of the phosphorylated form of
STAT 1 was performed with an antibody specific for phosphorylation on tyrosine 701 (STAT 1 Y701). Analysis with either
one of these STAT 1 antibodies demonstrates the presence of
STAT 1 in the nucleus following a 30-min IFN-␥ stimulation.
However, the STAT 1 Y701 antibody is more sensitive, and we
observed this protein in the nucleus even after a 12-h IFN-␥
treatment. We have previously reported that STAT 5A is present in the nucleus of adipocytes under basal conditions (15),
and IFN-␥ treatment does not cause a redistribution of this
protein. Therefore, STAT 5A (Fig. 3, bottom panel) is shown to
indicate the even loading of both cytosolic and nuclear samples.
The rapid loss of PPAR␥1 and -␥2 proteins in the presence of
IFN-␥ suggested that the PPAR␥ proteins may be labile. Therefore, we examined the decay of PPAR␥ and STATs in 3T3-L1
adipocytes. Whole cell extracts were isolated from 3T3-L1 adipocytes at various times following the addition of 5 M cycloheximide (⫹CH) or ethanol (⫺CH), a vehicle control. As shown
in Fig. 4, the inhibition of protein synthesis resulted in the loss

FIG. 2. IFN-␥ treatment results in a rapid loss of PPAR␥ expression in adipocytes. Whole cell extracts were prepared from fully
differentiated 3T3-L1 adipocytes following a treatment with 100
units/ml IFN-␥ as indicated at the top of the figure. One hundred g of
each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. The molecular mass of each
protein is indicated to the left of the blot in kilodaltons. Samples were
processed and results were visualized as described in the legend to Fig.
1. This is a representative experiment independently performed three
times. (JAK1, the kinase that activates STAT1 in adipocytes.

FIG. 3. IFN-␥ treatment results in a decrease of nuclear PPAR␥
and an increase in cytosolic STAT 1 in adipocytes. Cytosolic and
nuclear extracts were isolated from fully differentiated 3T3-L1 adipocytes following treatment with IFN-␥ as indicated at the top of the
figure. One hundred g of each extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.
Samples were processed and results were visualized as described in the
legend to Fig. 1. This is a representative experiment independently
performed two times.

of PPAR␥ by 12 h with over half of the protein decayed by 6 h.
A log plot of the remaining protein versus time was used to
estimate the half-life of PPAR␥ and of adipocyte-expressed
STAT proteins. The estimated half-life of these proteins is
indicated in Fig. 4 and is an average calculation of three inde-

IFN-␥ Effects on PPAR␥

FIG. 4. The turnover of PPAR␥ and adipocyte-expressed STAT
proteins. Whole cell extracts were prepared from 3T3-L1 adipocytes
following various periods of treatment with 5 M cycloheximide (⫹CH)
or ethanol (⫺CH), a vehicle control. One hundred g of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. Samples were processed and results were visualized as described in the legend to Fig. 1. This is a representative
experiment independently performed three times.

pendent experiments. PPAR␥1 and -␥2 are labile compared
with the STAT proteins, which have half-lives at least twice as
long as the PPAR␥ proteins. We also investigated the effect of
IFN-␥ on PPAR␥ in the presence of cycloheximide. Because of
experimental variability, it was difficult to quantitate the decrease in the half-life of the PPAR␥ proteins in the presence of
IFN-␥. However, in each experiment, the decay of the PPAR␥
was quicker in the presence of IFN-␥, as shown in Fig. 5.
Adipocytes were treated with 5 M cycloheximide in the presence or absence of IFN-␥, and whole cell extracts were isolated
at 0, 1, and 4 h. As shown in Fig. 5, the decay of both PPAR␥2
and -␥1 is increased in the presence of IFN-␥ with a complete
loss of PPAR␥1 at 4 h.
TZD treatment has also been shown to decrease PPAR␥
expression. Therefore, we compared the effects of IFN-␥ and
englitazone (ENG), a TZD, on the expression of PPAR␥ in
adipocytes. As shown in Fig. 6, fully differentiated adipocytes
were exposed to IFN-␥ or ENG alone or in combination. In the
first combination, adipocytes were treated with IFN-␥ 1 h prior
to the addition of englitazone. In the second combination, adipocytes were treated with englitazone 1 h prior to the addition
of IFN-␥. For each combination, whole cell extracts were isolated 5 h after initiation of the experiment. These results demonstrate that the combination of both inhibitors of PPAR␥
expression resulted in an even greater decrease in PPAR␥
expression than one agonist alone.
The results of the cycloheximide experiments in Fig. 5 suggest that the decay of PPAR␥2 and -␥1 is increased in the
presence of IFN-␥. Therefore, we examined PPAR␥ expression
in the presence of proteasome inhibitors. As shown in Fig. 7, a
6-h treatment of either epoxomicin or lactacystin had little
effect on the levels of PPAR␥2 or -␥1 protein. A 6-h IFN-␥
treatment resulted in a substantial loss of PPAR␥ protein, but
the IFN-␥-induced loss of PPAR␥2 and -␥1 was inhibited in the
presence of either epoxomicin or lactacystin. Notably, the presence of these two different proteasome inhibitors did not restore PPAR␥2 and -␥1 to the levels found in untreated adipocytes, suggesting that protein degradation is only one manner
in which IFN-␥ regulates PPAR␥ expression. In the presence of
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FIG. 5. PPAR␥ turnover is increased in the presence of IFN-␥.
Whole cell extracts were prepared from 3T3-L1 adipocytes following
various periods of treatment with 5 M cycloheximide or ethanol in the
presence or absence of IFN-␥. One hundred g of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. Samples were processed and results were visualized as described in the legend to Fig. 1. This is a representative
experiment independently performed three times.

FIG. 6. The IFN-␥-induced increase of PPAR␥ expression is
even greater in the presence of englitazone. Whole cell extracts
were prepared from fully differentiated 3T3-L1 adipocytes following a
5-h treatment of IFN-␥, ENG, IFN-␥ ⫹ ENG (added 1 h after the
addition of IFN-␥), and ENG ⫹ IFN-␥ (added 1 h after the addition of
ENG). One hundred g of each extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.
Samples were processed and results were visualized as described in the
legend to Fig. 1. CTL, control.

the two proteasome inhibitors, there were no differences in the
levels of any STATs or ERK1/ERK2. Interestingly, the IFN-␥induced increase in STAT 1 was blunted in the presence of
epoxomicin or lactacystin, suggesting that the IFN-␥-induced
increase in STAT 1 may be dependent on the degradation of
some protein(s).
These experiments indicate that, in addition to having an
effect on the turnover of the PPAR␥ proteins, there is presumably another means by which IFN-␥ causes a decrease in
PPAR␥ expression. Therefore, we examined the effect of IFN-␥
on PPAR␥ mRNA accumulation. As shown in Fig. 8, a 2-h
IFN-␥ treatment resulted in a substantial loss of PPAR␥
mRNA. Northern blot analysis cannot distinguish between the
two forms of PPAR␥. A decrease in C/EBP␣ and GLUT4 was
also observed following a 20-h IFN-␥ treatment. In addition, we
observed an increase in the levels of both C/EBP␤ and C/EBP␦
following an IFN-␥ treatment. A notable decrease in aP2/422
was observed after a 12-h treatment with IFN-␥. The expression of glycerol phosphate dehydrogenase (GPD), a gene whose
expression is elevated in adipocytes, was substantially decreased following a 20-h treatment with IFN-␥. Following a
24-h IFN-␥ treatment, there was also a slight decline in adipsin
mRNA. The hybridization of ␤-actin is shown to represent the
even loading of the samples.
Because the IFN-␥-induced loss of PPAR␥ mRNA was relatively rapid, we predicted that the decay of the PPAR␥ mRNA
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FIG. 7. The IFN-␥-induced decrease of PPAR␥ is partially inhibited in the presence of proteasome inhibitors. Whole cell extracts were prepared from fully differentiated 3T3-L1 adipocytes following a 6-h treatment of either 100 nM epoxomicin or 5 M lactacystin
in the presence or absence of IFN-␥ (100 units/ml). One hundred g of
each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. Samples were processed and
results were visualized as described in the legend to Fig. 1. This is a
representative experiment independently performed three times. CTL,
control.

would be brief compared with C/EBP␣. Therefore, we investigated the turnover of these two transcription factor mRNAs.
Total RNA was isolated from cells at various times after treatment with actinomycin D. As shown in Fig. 9A, the PPAR␥
mRNA decayed rapidly compared with the C/EBP␣ mRNA. We
estimated the half-life of the PPAR␥ mRNA to be less than 3 h.
We also examined the decay of PPAR␥ in the presence of IFN-␥
to determine whether this growth factor had any effect on the
stability of the PPAR␥ mRNA. We found that the decay of
PPAR␥ mRNA was not altered in the presence of IFN-␥ as
indicated in Fig. 9B. These results strongly suggested that
IFN-␥ would have an effect on the transcription of PPAR␥.
To determine whether the IFN-␥-induced changes in PPAR␥
and C/EBP␣ mRNA accumulation shown in Fig. 8 were attributable to the effects on synthesis, we measured the transcription rates of these genes in nuclei isolated from control and
IFN-␥-treated adipocytes. Fully differentiated 3T3-L1 adipocytes were exposed to cycloheximide (⫾IFN-␥) for 1 h. As shown
in Fig. 10, a substantial suppression of both PPAR␥ and
C/EBP␣ was observed following IFN-␥ treatment, indicating
that the effect of IFN-␥ on the transcription of these genes was
independent of new protein synthesis. IFN-␥ had no effect on
␤-actin transcription (data not shown).
IFN-␥ is known to have effects on both lipolysis and lipogenesis, so we investigated the effect of this growth factor on basal
and insulin-sensitive glucose uptake. As shown in Table I,
serum-deprived 3T3-L1 adipocytes had a 6.7-fold increase in
glucose uptake following a 10-min treatment of 100 nM insulin.
After a 24-h treatment of IFN-␥, cultured adipocytes were still
responsive to insulin (6.13-fold increase). However, following a
48-h treatment of IFN-␥, when both PPAR␥ and C/EBP␣ were
substantially decreased (Fig. 1), there was a discernible decrease in insulin-stimulated glucose uptake (4.42-fold in-

FIG. 8. IFN-␥ treatment results in a rapid loss of PPAR␥ mRNA
and a decrease in expression of other adipocyte markers. Total
RNA was isolated from fully differentiated 3T3-L1 adipocytes following
treatment with IFN-␥ as indicated at the top of the figure. Twenty g of
total RNA was electrophoresed, transferred to nylon, and subjected to
Northern blot analysis. This is a representative experiment independently performed two times. GPD, glycerol phosphate dehydrogenase.

crease). Exposure to IFN-␥ for 72 and 96 h had no effect on
basal glucose uptake but resulted in a substantial decrease in
insulin-sensitive glucose uptake. Following a 96-h IFN-␥ exposure, there was only a 2.2-fold increase following insulin treatment. IFN-␥ treatment for more than 96 h did not result in a
further decline of insulin-sensitive glucose uptake (data not
shown). The IFN-␥-induced effects on insulin sensitivity do not
appear to be a result of any significant lipid loss as there were
no distinguishable differences in Oil Red O staining from control and IFN-␥-treated (96 h) adipocytes (data not shown).
DISCUSSION

IFN-␥ affected the expression of many adipocyte transcription factors, including PPAR␥2 and -␥1, C/EBP␣, C/EBP␤,
C/EBP␦, SREBP-1, STAT 1, and STAT 3. However, the most
profound effect of IFN-␥ was on PPAR␥ expression. These
studies have also revealed that both the PPAR␥ mRNA and
protein are labile compared with other adipocyte transcription
factors. IFN-␥ treatment of adipocytes leads to a decrease in
PPAR␥ that is the result of the inhibition of transcription
coupled with an increase in the degradation of PPAR␥2 and
-␥1. Interestingly, recent studies have revealed that thiazolidinedione treatment of the 3T3-F442A adipocytes results in a
reduction of PPAR␥ protein that is distinct from mRNA regulation (18). In that study, the data indicated that the TZD
treatment of adipocytes resulted in the ubiquitination of
PPAR␥ and subsequent degradation that was dependent on the
proteasome complex (18). These results are comparable with
the effects we observed with IFN-␥. In our studies, two distinct
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FIG. 9. PPAR␥ mRNA is more labile
than C/EBP␣ mRNA in adipocytes,
and the decay of these mRNAs is not
affected by IFN-␥. A, total RNA was
isolated from fully differentiated 3T3-L1
adipocytes following treatment with 5
g/ml actinomycin D for the various periods of time indicated at the top of the
figure. Control samples (⫺actinomycin D)
were isolated at the start and finish of the
experiment. B, total RNA was isolated
from fully differentiated 3T3-L1 adipocytes following treatment with 5 g/ml
actinomycin D for the various periods of
time indicated at the top of the figure in
the absence or presence of IFN-␥. In each
experiment, 20 g of total RNA was electrophoresed, transferred to nylon, and
subjected to Northern blot analysis for
C/EBP␣ and PPAR␥. This is a representative experiment independently performed two times.

TABLE I
The effect of IFN-␥ on insulin-sensitive glucose transport
Basal

Insulin-stimulated

-Fold
increase

pmol/min/mg protein

FIG. 10. IFN-␥ treatment results in a suppression of PPAR␥
and C/EBP␣ transcription in adipocytes in a manner that is
independent of new protein synthesis. Nuclei were isolated from
fully differentiated adipocytes that were exposed to 5 mM cycloheximide
in the presence or absence of IFN-␥ for 1 h. Nuclei were subjected to
run-on analysis, and the autoradiogram displayed isa representative of
an experiment performed twice with independent preparations of nuclei. CTL, control.

proteasome inhibitors affected PPAR␥2 and -␥1 protein levels
in the presence of IFN-␥ but had little effect in adipocytes
lacking cytokine stimulation. In summary, both TZD and
IFN-␥ treatments of adipocytes appear to target PPAR␥ to the
proteasome for degradation. Moreover, our observations on the
lability of PPAR␥ proteins suggest that PPAR␥ turnover is an
important event.
The inhibition of proteasome activity in the presence of
IFN-␥ did not restore the PPAR␥ proteins to normal cellular
levels, and we observed a potent effect of IFN-␥ on PPAR␥
transcription and mRNA accumulation. These results have led

Control
24-h IFN-␥
48-h IFN-␥
72-h IFN-␥
96-h IFN-␥

67 ⫾ 12
64 ⫾ 4
66 ⫾ 10
56 ⫾ 6
53 ⫾ 8

449 ⫾ 38
392 ⫾ 40
292 ⫾ 28
212 ⫾ 20
117 ⫾ 13

6.70
6.13
4.42
3.80
2.20

us to hypothesize that IFN-␥-induced STAT 1 activation in fat
cells may be responsible for the transcriptional suppression of
PPAR␥. Cross-talk between STATs and PPARs has been demonstrated in liver cells (22). We are currently initiating studies
to identify the IFN-␥-sensitive element in the PPAR␥ promoters and determine whether STAT 1 is directly involved in the
transcriptional suppression of PPAR␥. Although STATs are
generally thought to be transcriptional activators, there is evidence that this family of transcription factors can also act as
repressors of transcription (23). These studies have led us to
hypothesize that IFN-␥-induced STAT 1 dimers directly bind
to the PPAR␥ promoters and result in an inhibition of
transcription.
The effects of IFN-␥ on PPAR␥ degradation are less expected.
Numerous studies have shown that serine phosphorylation of
PPAR␥ on Ser112 by mitogen-activated protein kinases (ERK1/
ERK2 and stress-activated protein kinase/c-Jun NH2-terminal
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kinase) results in a strong suppression of PPAR␥ activity (24 –
27), which in part appears to involve ligand binding (28). Our
previous studies in the 3T3-L1 adipocytes have demonstrated
that IFN-␥ resulted in both STAT 1 and STAT 3 tyrosine
phosphorylation and nuclear translocation (15). However, unlike other cytokines, IFN-␥ did not result in the activation of
ERK1/ERK2 in adipocytes. Therefore, it does not appear that
ERK1/ERK2-induced serine phosphorylation of PPAR␥ could
be involved in the effects of IFN-␥ that we observed on PPAR␥
degradation. Our results are supported by the findings of
Spiegelman and co-workers (18), which indicate that the phosphorylation of PPAR␥ on Ser112 is not required for its downregulation. However, we have not examined the role of serine
phosphorylation in the IFN-␥-induced PPAR␥ degradation or
the effect of IFN-␥ on the activation of c-Jun NH2-terminal
kinase in adipocytes.
Although the mechanism by which IFN-␥ directs PPAR␥ to
the proteasome for degradation is not known, it is clear that the
turnover of PPAR␥ is further increased when both IFN-␥ and a
PPAR␥ ligand are present. Perhaps IFN-␥ could either modulate the phosphorylation state of PPAR␥ or have an effect on
the synthesis of an endogenous PPAR␥ ligand. Alternatively,
IFN-␥-induced PPAR␥ degradation could occur via a pathway
that is independent of ligand-induced degradation. It is interesting to note that the analysis of PPAR␥ mutants by the
Spiegelman laboratory demonstrated that the TZD-induced
PPAR␥ decay was not strictly dependent on its transcriptional
activity but was dependent upon the ligand-gated activation
function (AF-2) domain. In these studies, ligand binding and
the activation of the AF-2 domain not only increased the transcriptional function of PPAR␥ but also induced ubiquitination
and subsequent proteasomal degradation.
Unlike TZDs, which are insulin sensitizers, IFN-␥ treatment
of adipocytes resulted in a condition of insulin resistance, as
measured by insulin-sensitive glucose uptake and a decrease in
the expression of adipocyte genes, such as GLUT4, aP2/422,
GPD, and adipsin. PPAR␥ has been implicated in the regulation of systemic insulin sensitivity, and some PPAR␥ mutations
are associated with severe insulin resistance and diabetes mellitus (29). In our studies, the most profound effect of IFN-␥ was
on PPAR␥ expression, which was significantly decreased after
only 6 h. Interestingly, we did not observe any substantial
effects on insulin-sensitive glucose uptake even after a 24-h
treatment of IFN-␥ despite the dramatic loss of PPAR␥ expression. Following a 48-h treatment, we did observe a substantial
inhibition of insulin-sensitive glucose uptake. At this time,
there was also a marked effect on C/EBP␣ expression. These
studies suggest that the loss of PPAR␥ may be insufficient to
confer insulin resistance in 3T3-L1 adipocytes. However, the
low levels of PPAR␥ observed after a 24- and 48-h IFN-␥ treatment may be sufficient levels of PPAR␥ expression to account
for the insulin responsiveness of these cells. Alternatively, the
primary role of PPAR␥ may be to regulate the expression of

other transcription factors, such as C/EBP␣. Nonetheless, the
increase in PPAR␥ turnover and the inhibition of PPAR␥ synthesis induced by IFN-␥ are prominent because of the relatively
rapid decay of both the PPAR␥ mRNA and the protein. Because
the regulation of PPAR␥ is the first observed effect of IFN-␥ on
adipocyte transcription factor expression, this event is likely
very important in the development of IFN-␥-induced insulin
resistance. IFN-␥ treatment also results in a decrease of
GLUT4, aP2, GPD, and adipsin expression in adipocytes. However, there is no notable difference in the morphology of the
cells, and there is no observable difference in Oil Red O staining from untreated 3T3-L1 fully differentiated adipocytes and
those that have been treated for 96 h with IFN-␥ (data not
shown). In conclusion, the tightly controlled regulation of
PPAR␥ synthesis and degradation that we observed in the
presence of IFN-␥ suggests that the cellular levels of PPAR␥
are a meaningful effector of gene expression.
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